Overview
Tamoxifen Resistance in Women With Stage I, Stage II, Stage IIIA, or Stage IIIB Breast Cancer
Status:
Terminated
Terminated
Trial end date:
2012-06-01
2012-06-01
Target enrollment:
0
0
Participant gender:
Female
Female
Summary
RATIONALE: Studying samples of blood from patients with breast cancer in the laboratory may help doctors identify and learn more about biomarkers related to tamoxifen resistance. PURPOSE: This laboratory study is looking at tamoxifen resistance in women with stage I, stage II, stage IIIA, or stage IIIB breast cancer.Accepts Healthy Volunteers?
NoDetails
Lead Sponsor:
Comprehensive Cancer Center of Wake Forest University
Wake Forest University Health SciencesCollaborator:
National Cancer Institute (NCI)Treatments:
Tamoxifen
Criteria
Inclusion Criteria:- Histologically confirmed invasive breast cancer
- Initial pathologic stage I-IIIB disease
- No stage IV disease
- Meets the following criteria for breast cancer therapy:
- Received prior primary local therapy for breast cancer
- Scheduled to begin tamoxifen citrate as adjuvant therapy for breast cancer within
3 weeks
- Hormone receptor status:
- Estrogen-receptor positive tumor
- Female
- Pre- or post-menopausal
- Must be able to donate 20 mL of blood
Exclusion Criteria:
- Severe anemia, defined as hemoglobin < 11 g/dL
- Psychiatric history that would preclude obtaining informed consent